GlassScriptPhysician profile
Kenneth Manas
NPI 1700803525
$1,785.99
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $357 · 2021: $629 · 2022: $119.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.97 | 2019-2022 | |
| Janssen Biotech, INC. | $349.91 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.88 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.85 | 2019-2021 | |
| Pfizer INC. | $83.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.81 | 2019-2021 | |
| Shire North American Group INC | $42.40 | 2019 | |
| Braintree Laboratories, INC. | $41.78 | 2020-2021 | |
| Ucb, INC. | $40.14 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $17.47 | 2019 | |
| Qol Medical, LLC | $15.21 | 2019 | |
| Boston Scientific Corporation | $13.19 | 2019 | |
| Covidien LP | $12.22 | 2019 | |
| Cook Medical LLC | $12.14 | 2019 | |
| Gilead Sciences, INC. | $11.16 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Manas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.